Fibrinolytic function and coronary risk

Current Cardiology Reports

Volumn 1, Issue 2, 1999, Pages 119-124

  Juhan Vague, Irène ^a   Morange, Pierre ^a   Alessi, Marie Christine ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

CORONARY ARTERY DISEASE; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLISM; OBESITY; PHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR;

CORONARY DISEASE; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033155967     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0069-x     Document Type: Article

References (70)

1. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991, 78:3114-3124.
2. Reilly CF, Fujita T, Hutzelmann JE, et al.: Plasminogen activator inhibitor 1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation 1991, 84:287-292.
3. Erickson LA, Fici GJ, Lund JE, et al.: Development of venous occlusions in mice transgenic for the PAI-1 gene. Nature 1990, 346:74-76.
4. Carmeliet P, Bouche A, De Clercq C, et al.: Biological effects of disruption of the tissue-type plasminogen activator, urokinase type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 1995, 748:367-382.
5. Farrehi PM, Ozaki CK, Carmeliet P, et al.: Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998, 97:1002-1008.
6. Stefansson S, Lawrence DA: The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectin. Nature 1996, 323:441-443.
7. Deng G, Curriden SA, Wang S et al.: Is plasminogen activator inhibitor 1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996, 134:1563-1571.
8. Chandler WL, Alessi MC, Aillaud MF, et al.: Clearance of t-PA and t-PA/PAI-1 complex: relationship to elevated t-PA antigen in patients with high PAI-1 activity levels. Circulation 1997, 96:761-768.
9. Juhan-Vague I, Alessi MC: Fibrinolysis and risk of coronary artery disease: Fibrinolysis 1996, 10: 127-136.
10. Scarabin PY, Aillaud MF, Amouyel P, et al.: Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime Study. Thromb Haemost 1998, 80:749-756.
11. Folsom AR, Pankow JS, Williams RR, et al.: Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI family heart study. Thromb Haemost 1998, 79:400-404.
12. Schneiderman J, Sawdey MS, Keeton MR, et al.: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992, 89:6998-7002.
13. Chomiki N, Henry M, Alessi MC, et al.: Plasminogen activator inhibitor 1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994, 72:44-53.
14. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al.: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998, 97:2213-2221.
15. Meade TW, Ruddock V, Stirling Y, et al.: Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993, 342:1076-1079.
16. Ridker PM, Vaughan DE, Stampfer MJ, et al.: Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168.
17. Lowe GDO, Yarnell JWG, Sweetnam PM, et al.: Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998, 79:129-133.
18. Thogersen AM, Jansson JH, Boman K, et al.: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98:2241-2247.
19. Hamsten A, De Faire U, Walldius G, et al.: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, II:3-9.
20. Jansson JH, Olofsson BO, Nilsson TK: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7 year follow up. Circulation 1993, 88:2030-2034.
21. Munkvad S, Gram J, Jespersen J: A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990, 11: 525-528.
22. Cortellaro M, Cofrancesco E, Boschetti C, et al.: Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993, 13:1412-1417.
23. Thompson SG, Kienast J, Pyke SDM, et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995, 332:635-641.
24. Juhan-Vague I, Pyke SDM, Alessi MC, et al.: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996, 94:2057-2063.
25. Held C, Hjemdhal P, Rehnqvist N, et al.: Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation 1997, 95:2380-2386.
26. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991, 34:457-462.
27. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993, 13:1865-1873.
28. Potter van Loon BJ, Kluft C, Radder JK, et al.: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993, 42:945-949.
29. McGill JB, Schneider DJ, Arfken CL, et al.: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994, 43:104-109.
30. Nagi DK, Hendra TJ, Ryle AJ, et al.: The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non insulin dependent) diabetic subjects. Diabetologia 1990, 33:532-537.
31. Juhan-Vague I, Alessi MC, Joly P, et al.: Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989, 9:362-367.
32. Haverkate F, Thompson SG, Duckert F: Haemostasis factors in angina pectoris: relation to gender, age and acute-phase reaction. Thromb Haemost 1995, 73:561-567.
33. Bavenholm P, De Faire U, Landou C, et al.: Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J 1998, 19:402-410.
34. Sakata K, Miura F, Sugino H, et al.: Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996, 131:1-6.
35. Ridker PM, Hennekens CH, Cerskus A, et al.: Plasma concentration of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994, 90:2236-2240.
36. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
37. Eschwege E, Richard JL, Thibult N, et al.: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985, 15:41-46.
38. Desprès JP, Lamarche B, Mauriège P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
39. Folsom AR, Qamhieh HT, Wing RR, et al.: Impact of weight loss on plasminogen activator inhibitor (PAI-1) factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993, 13:162-169.
40. Samad F, Yamamoto K, Loskutoff DJ: Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. J Clin Invest 1996, 97:37-46.
41. Lundgren CH, Brown SL, Nordt TD, et al.: Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996, 93:106-110.
42. Shimomura I, Funahashi T, Takahashi M, et al.: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996, 2:800-803.
43. Alessi MC, Peiretti F, Morange P, et al.: Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997, 46:860-867.
44. Björntorp P: "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990, 10: 493-496.
45. Cigolini M, Targher G, Bergamo Andreis IA, et al.: Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996, 16:368-374.
46. Janand delenne B, Chagnaud C, Raccah D, et al.: Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998, 22:312-317.
47. Morange PE, Alessi MC, Verdier M, et al.: PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Possible contribution of local TNF - a and TGF - b. Arterioscler Thromb Vasc Biol 1999, 19:1361-1365.
48. Samad F, Loskutoff DJ: The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemost 1997;78:652-655.
49. Morange PE, Aubert J, Peiretti F, et al.: Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999, 48:890-895.
50. Ridker PM, Gaboury CL, Conlin PR, et al.: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993, 87: 1969-1973.
51. Wright RA, Flapan AD, Alberti KG, et al.: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994, 24:67-73.
52. Margaglione M, Cappucci G, d'Addedda M, et al.: PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998, 18:562-567.
53. Jeng JR, Harn HJ, Yueh KC, et al.: Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension. Am J Hypertens 1998, 11:235-239.
54. Dawson S, Hamsten A, Wiman B, et al.: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991, 11: 183-190.
55. Dawson SJ, Wiman B, Hamsten A, et al.: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) gene respond differently to interleukin 1 in HepG2 cells. J Biol Chem 1993, 268:10739-10745.
56. Henry M, Chomiki N, Scarabin PY, et al.: Five frequent polymorphisms of plasminogen activator inhibitor 1 gene: lack of association between genotypes, PAI activity and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997, 17:851-858.
57. Ye S, Green FR, Scarabin PY, et al.: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1(PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995, 74:837-841.
58. Panahloo A, Mohamed-Ali V, Lane A, et al.: Determinants of plasminogen activator 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995, 44:37-42.
59. Eriksson P, Kallin B, van't Hooft, et al.: Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995, 92:1851-1855.
60. Mansfield MW, Strickland MH, Grant PJ: Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor 1 in caucasian patients with non insulin dependent diabetes mellitus. Thromb Haemost 1995, 74:842-848.
61. Ossei-Gerning N, Mansfield MW, Stickland MH, et al.: Plasminogen activator inhibitor 1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997, 17:33-37.
62. Burzotta F, Di Castelnuovo A, Amore C, et al.: 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI 1 activity in Italians: a model of gene environment interaction. Thromb Haemost 1998, 79:354-358.
63. Ridker PM, Hennekens CH, Lindpaintner K, et al.: Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997, 95:59-62.
64. Burzotta F, Di Castelnuovo A, Amore C, et al.: 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction: a case control study in a sample of GISSI 2 patients. Thromb Haemost 1997, 78:1294-1295.
65. Margaglione M, Cappucci G, Colaizzo D, et al.: The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18:152-156.
66. Iacovello L, Burzotta F Di Castelnuovo A, et al.: The 4G/5G polymorphism of PAI 1 promoter gene as a risk factor for myocardial infarction: a meta analysis. Blood Coagul Fibrinolysis 1997, 8:20.
67. Henry M, Tregouët DA, Alessi MC, et al.: Metabolic determinants are much more important than genetic polymor phisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 1998, 18:84-91.
68. Van den Bom JG, De Knijff P, Haverkate F et al.: Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997, 95:2623-2627.
69. Ridker PM, Baker MT, Hennekens CH, et al.: Alu repeat polymorphism in the gene coding for tissue type plasm inogen activator (t-PA) and risk of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol 1997, 17:1687-1690.
70. Friederich PW, Levi M, Biemond BJ, et al.: Novel low molecular weight inhibitor of PAI 1 (XR5118) promotes endogenous fibrinolysis and reduces post thrombolysis thrombus growth in rabbits. Circulation. 1997, 96:916-921.